{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:29:26Z","timestamp":1788834566877,"version":"build-2803163510"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,16]],"date-time":"2020-12-16T00:00:00Z","timestamp":1608076800000},"content-version":"am","delay-in-days":350,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.intimp.2019.106080","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T05:25:15Z","timestamp":1576473915000},"page":"106080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Exogenous hormones and hereditary angioedema"],"prefix":"10.1016","volume":"78","author":[{"given":"Anne","family":"Gompel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Boccon-Gibod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Gobert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2019.106080_b0005","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/B978-0-12-800100-4.00002-7","article-title":"Pathogenic mechanisms of BK mediated diseases: dysregulation of an innate inflammatory pathway","volume":"121","author":"Kaplan","year":"2014","journal-title":"Adv. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2019.106080_b0010","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.jaci.2016.02.021","article-title":"Plasmin is a natural trigger for BK production in patients with hereditary angioedema with factor XII mutations","volume":"138","author":"de Maat","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2019.106080_b0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13104-019-4335-8","article-title":"Increased fibrinolysis-induced BK formation in hereditary angioedema confirmed using stored plasma and biotechnological inhibitors","volume":"12","author":"Marceau","year":"2019","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.intimp.2019.106080_b0020","first-page":"251","article-title":"The estrogen trinity: membrane, cytosolic, and nuclear effects","volume":"16","author":"Nadal","year":"2001","journal-title":"News Physiol Sci. Int. J. Physiol. Prod. Jointly Int. Union Physiol. Sci. Am. Physiol. Soc."},{"key":"10.1016\/j.intimp.2019.106080_b0025","doi-asserted-by":"crossref","unstructured":"Guivarc\u2019h E, Buscato M, Guihot A-L, Favre J, Vessi\u00e8res E, Grimaud L, et al. Predominant Role of Nuclear Versus Membrane Estrogen Receptor \u03b1 in Arterial Protection: Implications for Estrogen Receptor \u03b1 Modulation in Cardiovascular Prevention\/Safety. J. Am. Heart Assoc. 2018 Jun 29;7(13).","DOI":"10.1161\/JAHA.118.008950"},{"issue":"5","key":"10.1016\/j.intimp.2019.106080_b0030","first-page":"762","article-title":"Rapid fibrinolysis, augmented Hageman factor (factor XII) titers, and decreased C1 esterase inhibitor titers in women taking oral contraceptives","volume":"96","author":"Gordon","year":"1980","journal-title":"J. Lab. Clin. Med."},{"issue":"1","key":"10.1016\/j.intimp.2019.106080_b0035","first-page":"52","article-title":"Dose-dependent effects of postmenopausal estrogen and progestin on antithrombin III and factor XII","volume":"111","author":"Gordon","year":"1988","journal-title":"J. Lab. Clin. Med."},{"issue":"2","key":"10.1016\/j.intimp.2019.106080_b0040","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1055\/s-0038-1657871","article-title":"Increased euglobulin fibrinolytic potential in women on oral contraceptives low in oestrogen\u2013levels of extrinsic and intrinsic plasminogen activators, prekallikrein, factor XII, and C1-inactivator","volume":"54","author":"Jespersen","year":"1985","journal-title":"Thromb. Haemost."},{"issue":"9","key":"10.1016\/j.intimp.2019.106080_b0045","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/clinchem\/31.9.1533","article-title":"Influence of oral contraceptives and pregnancy on constituents of the kallikrein-kininogen system in plasma","volume":"31","author":"Adam","year":"1985","journal-title":"Clin. Chem."},{"issue":"3 Pt 1","key":"10.1016\/j.intimp.2019.106080_b0050","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0091-6749(05)80025-9","article-title":"C1 esterase inhibitor in pregnancy","volume":"90","author":"Cohen","year":"1992","journal-title":"J. Allergy Clin. Immunol."},{"issue":"11","key":"10.1016\/j.intimp.2019.106080_b0055","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1210\/endo.136.11.7588244","article-title":"Molecular basis of estrogen regulation of Hageman factor XII gene expression","volume":"136","author":"Farsetti","year":"1995","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.intimp.2019.106080_b0060","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0049-3848(91)90343-U","article-title":"Contact activation factors in plasma from women using oral contraceptives\u2013increased levels of factor XII, kinin-free high molecular weight kininogen and acetone-activated kallikrein","volume":"64","author":"Hoem","year":"1991","journal-title":"Thromb. Res."},{"key":"10.1016\/j.intimp.2019.106080_b0065","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.vph.2015.10.004","article-title":"Estrogens are needed for the improvement in endothelium-mediated dilation induced by a chronic increase in blood flow in rat mesenteric arteries","volume":"80","author":"Tarhouni","year":"2016","journal-title":"Vasc.Pharmacol."},{"issue":"11","key":"10.1016\/j.intimp.2019.106080_b0070","doi-asserted-by":"crossref","first-page":"E44","DOI":"10.1161\/01.RES.87.11.e44","article-title":"Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae","volume":"87","author":"Chambliss","year":"2000","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.intimp.2019.106080_b0075","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0014-2999(98)00787-0","article-title":"17Beta-estradiol acutely improves endothelium-dependent relaxation to BK in isolated human coronary arteries","volume":"362","author":"Barton","year":"1998","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.intimp.2019.106080_b0080","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1210\/er.2009-0034","article-title":"Kallikreins on steroids: structure, function, and hormonal regulation of prostate-specific antigen and the extended kallikrein locus","volume":"31","author":"Lawrence","year":"2010","journal-title":"Endocr. Rev."},{"issue":"1","key":"10.1016\/j.intimp.2019.106080_b0085","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jaci.2016.09.032","article-title":"Cytokine and estrogen stimulation of endothelial cells augments activation of the prekallikrein-high molecular weight kininogen complex: Implications for hereditary angioedema","volume":"140","author":"Joseph","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2019.106080_b0090","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0015-0282(97)00220-3","article-title":"Fibrinogen and plasminogen modifications during oral estradiol replacement therapy","volume":"68","author":"Conard","year":"1997","journal-title":"Fertil. Steril."},{"issue":"8","key":"10.1016\/j.intimp.2019.106080_b0095","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/sj.bjp.0701255","article-title":"Regulation of BK B2-receptor expression by oestrogen","volume":"121","author":"Madeddu","year":"1997","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2019.106080_b0100","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/00042192-200105000-00011","article-title":"Effect of long-term hormone replacement therapy on angiotensin-converting enzyme activity and BK in postmenopausal women with essential hypertension and normotensive postmenopausal women","volume":"8","author":"Nogawa","year":"2001","journal-title":"Menopause N Y N."},{"issue":"4","key":"10.1016\/j.intimp.2019.106080_b0105","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1447-0594.2008.00474.x","article-title":"Effects of long-term transdermal hormone replacement therapy on the renin-angiotensin- aldosterone system, plasma BK levels and blood pressure in normotensive postmenopausal women","volume":"8","author":"Ichikawa","year":"2008","journal-title":"Geriatr Gerontol Int."},{"issue":"7","key":"10.1016\/j.intimp.2019.106080_b0110","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.amjhyper.2005.10.006","article-title":"Different effects of transdermal and oral hormone replacement therapy on the renin-angiotensin system, plasma BK level, and blood pressure of normotensive postmenopausal women","volume":"19","author":"Ichikawa","year":"2006","journal-title":"Am. J. Hypertens."},{"issue":"4","key":"10.1016\/j.intimp.2019.106080_b0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1470320308096405","article-title":"The BK-degrading aminopeptidase P is increased in women taking the oral contraceptive pill","volume":"9","author":"Cilia La Corte","year":"2008","journal-title":"J. Renin-Angiotensin-Aldosterone Syst. JRAAS"},{"issue":"5","key":"10.1016\/j.intimp.2019.106080_b0120","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3109\/13625187.2015.1050091","article-title":"Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: a literature review","volume":"20","author":"Lete","year":"2015","journal-title":"Eur. J. Contracept Reprod Health Care Off. J. Eur. Soc. Contracept."},{"issue":"347","key":"10.1016\/j.intimp.2019.106080_b0125","article-title":"Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis","volume":"12","author":"Stegeman","year":"2013","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.intimp.2019.106080_b0130","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1055\/s-0038-1641152","article-title":"Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism","volume":"118","author":"Hugon-Rodin","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.intimp.2019.106080_b0135","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/13625189909040809","article-title":"A comparative study of the hemostatic effects of two monophasic oral contraceptives containing 30 mu(g) ethinylestradiol and either 2 mg chlormadinone acetate or 150 mu(g) desogestrel","volume":"4","author":"Winkler","year":"1999","journal-title":"Eur. J. Contracept Reprod Health Care Off. J. Eur. Soc. Contracept."},{"issue":"5","key":"10.1016\/j.intimp.2019.106080_b0140","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.contraception.2009.12.009","article-title":"Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users","volume":"81","author":"Dore","year":"2010","journal-title":"Contraception."},{"issue":"4","key":"10.1016\/j.intimp.2019.106080_b0145","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1177\/0091270006297919","article-title":"Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive","volume":"47","author":"Devineni","year":"2007","journal-title":"J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.intimp.2019.106080_b0150","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.contraception.2005.03.005","article-title":"Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive","volume":"72","author":"van den Heuvel","year":"2005","journal-title":"Contraception."},{"issue":"6","key":"10.1016\/j.intimp.2019.106080_b0155","doi-asserted-by":"crossref","first-page":"R221","DOI":"10.1530\/EJE-14-0527","article-title":"Epidemiology of hormonal contraceptives-related venous thromboembolism","volume":"171","author":"Hugon-Rodin","year":"2014","journal-title":"Eur. J. Endocrinol."},{"issue":"4","key":"10.1016\/j.intimp.2019.106080_b0160","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0002-9343(02)01526-7","article-title":"Recurrent episodes of skin angioedema and severe attacks of abdominal pain induced by oral contraceptives or hormone replacement therapy","volume":"114","author":"Bork","year":"2003","journal-title":"Am. J. Med."},{"key":"10.1016\/j.intimp.2019.106080_b0165","doi-asserted-by":"crossref","unstructured":"Bouillet L, Longhurst H, Boccon-Gibod I, Bork K, Bucher C, Bygum A, et al. Disease expression in women with hereditary angioedema. Am. J. Obstet. Gynecol. 2008;199(5):484.e1-4.","DOI":"10.1016\/j.ajog.2008.04.034"},{"issue":"4","key":"10.1016\/j.intimp.2019.106080_b0170","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/cea.12055","article-title":"Benefits of progestin contraception in non-allergic angioedema","volume":"43","author":"Saule","year":"2013","journal-title":"Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2019.106080_b0175","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 - KYLEENA (l\u00e9vonorgestrel), dispositif intra-ut\u00e9rin avec progestatif. available from: https:\/\/www.has-sante.fr\/portail\/jcms\/c_2824470\/fr\/kyleena-levonorgestrel-dispositif-intra-uterin-avec-progestatif."},{"issue":"5","key":"10.1016\/j.intimp.2019.106080_b0180","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.lpm.2015.01.005","article-title":"[Hereditary angi\u0153dema treatments: recommendations from the French national center for angi\u0153dema (Bordeaux consensus 2014)]","volume":"44","author":"Bouillet","year":"1983","journal-title":"Presse Medicale Paris Fr"},{"key":"10.1016\/j.intimp.2019.106080_b0185","unstructured":"Jamin C, Intrator L, Laurent J, Lagrue G. [Cyproterone acetate is not effective in the prevention of hereditary angioneurotic edema]. Presse Medicale Paris Fr. 1983. 1985 Sep 7;14(29):1559\u201360."},{"issue":"4","key":"10.1016\/j.intimp.2019.106080_b0190","first-page":"301","article-title":"Recurrent angioedema associated with hypogonadism or anti-androgen therapy","volume":"63","author":"Pichler","year":"1989","journal-title":"Ann Allergy"},{"issue":"8","key":"10.1016\/j.intimp.2019.106080_b0195","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/bdd.2510120804","article-title":"Single oral dose pharmacokinetics and comparative bioavailability of danazol in humans","volume":"12","author":"Hooper","year":"1991","journal-title":"Biopharm. Drug Dispos."},{"issue":"1","key":"10.1016\/j.intimp.2019.106080_b0200","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0731-7085(90)80010-M","article-title":"A liquid chromatographic method for the determination of danazol in human serum","volume":"8","author":"Selinger","year":"1990","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"7","key":"10.1016\/j.intimp.2019.106080_b0205","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1093\/annonc\/mdp295","article-title":"Tamoxifen contraindicated in women with hereditary angioedema?","volume":"20","author":"Rousset-Jablonski","year":"2009","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"5","key":"10.1016\/j.intimp.2019.106080_b0210","doi-asserted-by":"crossref","first-page":"e237","DOI":"10.1111\/jdv.14056","article-title":"Tamoxifen may cause life-threatening angioedema attacks in patients with hereditary angioedema","volume":"31","author":"Bork","year":"2017","journal-title":"J. Eur. Acad Dermatol. Venereol. JEADV"},{"issue":"4","key":"10.1016\/j.intimp.2019.106080_b0215","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1080\/13697137.2018.1472567","article-title":"Progesterone for treatment of symptomatic menopausal women","volume":"21","author":"Prior","year":"2018","journal-title":"Climacteric J. Int. Menopause Soc."},{"issue":"9","key":"10.1016\/j.intimp.2019.106080_b0220","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1200\/JCO.2005.04.7324","article-title":"Phase III comparison of depomedroxyprogesterone acetate to venlafaxine for managing hot flashes: north central cancer treatment group trial N99C7","volume":"24","author":"Loprinzi","year":"2006","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2019.106080_b0225","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1210\/jc.2015-2236","article-title":"Treatment of symptoms of the menopause: an endocrine society clinical practice guideline","volume":"100","author":"Stuenkel","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.intimp.2019.106080_b0230","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1210\/jc.2017-01138","article-title":"Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors","volume":"102","author":"Santen","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.intimp.2019.106080_b0235","doi-asserted-by":"crossref","unstructured":"S. Salvi, M. Bonaf\u00e8, S. Bravaccini, Androgen receptor in breast cancer: A wolf in sheep\u2019s clothing? A lesson from prostate cancer. Semin. Cancer Biol. 2019 Apr 16; Epud Head of publication.","DOI":"10.1016\/j.semcancer.2019.04.002"},{"issue":"116","key":"10.1016\/j.intimp.2019.106080_b0240","first-page":"35","article-title":"Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers","volume":"3","author":"Rousset-Jablonski","year":"1990","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"10.1016\/j.intimp.2019.106080_b0245","doi-asserted-by":"crossref","unstructured":"T. Mizushima, H. Miyamoto, The Role of Androgen Receptor Signaling in Ovarian Cancer. Cells. 2019 Feb 19;8(2). Epud Head of publication.","DOI":"10.3390\/cells8020176"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919314699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576919314699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:18:40Z","timestamp":1761585520000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576919314699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":49,"alternative-id":["S1567576919314699"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2019.106080","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exogenous hormones and hereditary angioedema","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2019.106080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106080"}}